Phase III, international, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P + G) versus gemcitabine (G) for resected pancreatic cancer (APACT): Recurrence patterns.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.4_suppl.704
Abstract: 704Background: APACT did not meet the primary endpoint of independently assessed disease-free survival (DFS) with nab-P + G vs G; overall survival showed a nominal improvement. Here, we report recu... read more here.
Keywords: adjuvant nab; iii international; international randomized; phase iii ... See more keywords